Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0K0IW
|
|||
| Former ID |
DCL000093
|
|||
| Drug Name |
CRA-028129
|
|||
| Indication | Psoriatic disorder [ICD-11: EA90; ICD-9: 696] | Terminated | [1] | |
| Company |
Celera Genomics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Cathepsin S (CTSS) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Lysosome | |||
| Phagosome | ||||
| Antigen processing and presentation | ||||
| Tuberculosis | ||||
| NetPath Pathway | Leptin Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| Reactome | Endosomal/Vacuolar pathway | |||
| Degradation of the extracellular matrix | ||||
| Trafficking and processing of endosomal TLR | ||||
| Assembly of collagen fibrils and other multimeric structures | ||||
| MHC class II antigen presentation | ||||
| WikiPathways | Class I MHC mediated antigen processing & presentation | |||
| Trafficking and processing of endosomal TLR | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800022029) | |||
| REF 2 | Phase I clinical trial for cathepsin S inhibitor for psoriasis begins. Celera Genomics. 2005. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.